Regonol (pyridostigmine bromide injection) is an active cholinesterase inhibitor indicated as a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.
What Are Side Effects of Regonol?
Common side effects of Regonol are usually related to overdosage and include:
The dosage of Regonol is determined by a physician and is based on the patient's body weight.
What Drugs, Substances, or Supplements Interact with Regonol?
Regonol may interact with antibiotics, quinidine, and magnesium salts. Tell your doctor all medications and supplements you use.
Regonol During Pregnancy and Breastfeeding
During pregnancy, Regonol should be administered only if prescribed. It is unknown if it would affect a fetus. Consult your doctor before breastfeeding.
Additional Information
Our Regonol (pyridostigmine bromide injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Regonol Consumer Information
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using pyridostigmine and call your doctor at once if you have any of these serious side effects:
extreme muscle weakness;
loss of movement in any part of your body;
weak or shallow breathing;
slurred speech, vision problems; or
worsening or no improvement in your symptoms of myasthenia gravis.
Common side effects may include:
stomach pain, nausea, vomiting, diarrhea;
muscle cramps, twitching;
sweating, increased salivation;
cough with mucus;
rash; or
blurred vision.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The side effects of pyridostigmine bromide are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis, and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation, and weakness. Muscarinic side effects can usually be counteracted by atropine. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication. Thrombophlebitis has been reported subsequent to intravenous administration.
DRUG INTERACTIONS
Concomitant administration of REGONOL (pyridostigmine bromide injection, USP) and 4-aminopyridine has been reported to delay the onset of action of REGONOL9.
Antibiotics
Parenteral administration of high doses of certain antibiotics may intensify or produce neuromuscular block through their own pharmacologic actions. The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. If these or other newly introduced antibiotics are used in conjunction with nondepolarizing neuromuscular blocking drugs during surgery, unexpected prolongation of neuromuscular block or resistance to its reversal should be considered a possibility.
Other
Experience concerning injection of quinidine during recovery from use of nondepolarizing muscle relaxants suggest that recurrent paralysis may occur. This possibility must be considered when administering anticholinesterase agents to antagonize neuromuscular blockade induced by nondepolarizing muscle relaxants.
Electrolyte imbalance and diseases which lead to electrolyte imbalance, such as adrenal cortical insufficiency, have been shown to alter neuromuscular blockade. Depending on the nature of the imbalance, either enhancement or inhibition may be expected. Magnesium salts, administered for the management of toxemia of pregnancy, may enhance the neuromuscular blockade. The possibility that such circumstances may interfere with the restoration of neuromuscular function should be considered when administering REGONOL®.
Interactions With Laboratory Tests
None known.
REFERENCES
10. Gyermek L. The Glycopyrrolate-Pyridostigmine Combination. Anesthesiology Review 1978;5:19-22.
&Copy; Regonol Patient Information is supplied by Cerner Multum, Inc. and Regonol Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
